U.S. Markets closed

Revance reports 4Q loss

NEWARK, Calif. (AP) _ Revance Therapeutics Inc. (RVNC) on Monday reported a loss of $26.8 million in its fourth quarter.

The Newark, California-based company said it had a loss of 95 cents per share.

The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 82 cents per share.

The biopharmaceutical posted revenue of $75,000 in the period.

For the year, the company reported that its loss widened to $89.3 million, or $3.18 per share. Revenue was nearly unchanged at $300,000.

Revance shares have climbed roughly 2 percent since the beginning of the year. In the final minutes of trading on Monday, shares hit $21.10, a climb of 14 percent in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RVNC at https://www.zacks.com/ap/RVNC


Keywords: Revance Therapeutics, Earnings Report